For years, Kasia Lipska, MD, MHS, associate professor of medicine (endocrinology) at Yale School of Medicine (YSM), has been ...
As the treatment of obesity in the 21st century takes a monumental turn, the need for quality care is more pressing than ever: Tips for starting a new obesity-focused practice.
Weights, aerobics, and … Wegovy? Some in the fitness industry are moving to dispense the popular GLP-1 medications to club ...
Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot Deal Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of ...
Drugmakers are preparing to launch an estimated 13 new weight-loss treatments in the U.S. over the next five years, according ...
(The Hill) — The Centers for Medicare and Medicaid (CMS) has issued guidance allowing for the coverage of anti-obesity medications, but only in cases they are indicated for treating conditions ...
While the benefits are substantial, so too may be the costs as more and more drugs and patients receive coverage. Obesity prevalence ... prices for Wegovy , with a list price up to $1,349 and ...
LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. The ...
“It’s not all about weight loss,” he said, adding that semaglutide ... and often linked with obesity. The growing list of potential uses for obesity drugs has been driving up expectations ...
Ozempic and weight-loss drugs raise hopes for obesity, but complexities exist. The Ozempic buzz plays into ideas of fat stigma and fatphobia. The Ozempic doesn't work same for everyone.
She covered several of these themes and biotechnology research as it relates to the important trend of expanding use of GLP-1 medications for weight loss and the treatment of diseases associated ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BrainStorm Cell Therapeutics said the FDA agreed to a ...